06.12.2016
- Despite tremendous challenges facing the pharmaceutical industry, it continues with its commitment to innovation and the discovery of novel drugs to address unmet medical needs...
08.09.2016
- Despite tremendous challenges facing the pharmaceutical industry, it continues with its commitment to innovation and the discovery of novel drugs to address unmet medical needs...
13.06.2016
- Since the beginning of the 21st century, pharma M&A activity has exploded. Mergers and acquisitions, layoffs, and outsourcing of research and manufacturing have become common place...
04.04.2016
- In September of 2015, Siegfried completed all closing conditions for its acquisition of the custom synthesis business of BASF and parts of the German group’s active pharmaceutical...
25.09.2015
- Siegfried Holding, the Swiss drug contract manufacturer, said it has completed all closing conditions for its acquisition of the custom synthesis business of BASF and parts of the...
15.07.2015
- Germany’s antitrust authority Bundeskartellamt has approved BASF’s plans to sell its custom synthesis business, part of the Nutrition & Health division, and parts of its current...
07.05.2015
- BASF has announced that it will sell its custom synthesis business, part of its Nutrition & Health division, and parts of its current active pharmaceutical ingredients (APIs)...
02.12.2014
- Siegfried Group has acquired Hameln Pharma in Germany, consisting of Hameln Pharmaceuticals and Hameln RDS, with effect from end November 2014. Hameln Pharma is located in the city...
